Clinical value of guideline recommended molecular targets and genome targeted cancer therapies: cross sectional study
According to the ESCAT and ESMO-MCBS frameworks, about one eighth of genome based treatments for solid cancer were rated as likely to offer a high benefit to patients, whereas around a third were identified as offering a promising but unproven substantial benefit. Ensuring that NCCN recommendations are aligned with expected clinical benefits is crucial for promoting informed, evidence based, genomic guided treatment decisions.
Authors
- Thomas J. Hwang (ORCID: https://orcid.org/0000-0003-0717-1497)
- Jerry Avorn (ORCID: https://orcid.org/0000-0003-0255-2346)
- Ariadna Tibau (ORCID: https://orcid.org/0000-0003-0229-6987)
- Aaron Seth Kesselheim (ORCID: https://orcid.org/0000-0002-8867-2666)
Institutions
- Universitat Autònoma de Barcelona (ES)
- Brigham and Women's Hospital (US)
- Harvard University (US)
- Hospital de Sant Pau (ES)
- Dana-Farber Cancer Institute (US)
- Institut de Recerca Sant Pau (ES)
Publication Details
- Journal
- BMJ
- Published
- 2024-08-20
- DOI
- https://doi.org/10.1136/bmj-2023-079126
- Citations
- 3
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 0.86
Funders
- Arnold Ventures